2026-08-29T10:10:51Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/227872024-11-28T19:30:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16982
Repisalud author Rodriguez-Nunez, Olga author Periáñez Párraga, Leonor author Oliver, Antonio author Munita, Jose M author Bote, Anna author Gasch, Oriol author Nuvials, Xavier author Dinh, Aurelien author Shaw, Robert author Lomas, Jose M author Torres, Vicente author Caston, Juanjo author Araos, Rafael author Abbo, Lilian M author Rakita, Robert author Perez, Federico author Aitken, Samuel L author Arias, Cesar A author Luisa Martin-Pena, M author Colomar Ferra, Maria Asuncion author Belen Nunez, M author Mensa, Josep author Antonio Martinez, Jose author Soriano, Alex 2024-09-10T13:09:52Z 2024-09-10T13:09:52Z 2019-10 Rodriguez-Nunez O, Perianez-Parraga L, Oliver A, Munita JM, Bote A, Gasch O, et al. Higher MICs (> 2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam. Open Forum Infect Dis. 2019 Oct;6(10):ofz416. 10.1093/ofid/ofz416 2328-8957 Open Forum Infectious Diseases http://hdl.handle.net/20.500.13003/9654 31660373 L631636843 2-s2.0-85081575557 https://hdl.handle.net/20.500.12105/22787 510164000063 Background. Ceftolozane/tazobactam (C/T) efficacy and safety in ventilator-associated pneumonia (VAP) is being evaluated at a double dose by several trials. This dosing is based on a pharmacokinetic (PK) model that demonstrated that 3 g q8h achieved >= 90% probability of target attainment (50% fT > minimal inhibitory concentration [MIC]) in plasma and epithelial lining fluid against C/T-susceptible P. aeruginosa. The aim of this study was to evaluate the efficacy of different C/T doses in patients with lower respiratory infection (LRI) due to MDR- or XDR-P. aeruginosa considering the C/T MIC. Methods. This was a multicenter retrospective study of 90 patients with LRI caused by resistant P. aeruginosa who received a standard or high dose (HDo) of C/T. Univariable and multivariable analyses were performed to identify independent predictors of 30-day mortality. Results. The median age (interquartile range) was 65 (51-74) years. Sixty-three (70%) patients had pneumonia, and 27 (30%) had tracheobronchitis. Thirty-three (36.7%) were ventilator-associated respiratory infections. The median C/T MIC (range) was 2 (0.5-4) mg/L. Fifty-four (60%) patients received HDo. Thirty-day mortality was 27.8% (25/90). Mortality was significantly lower in patients with P. aeruginosa strains with MIC <= 2 mg/L and receiving HDo compared with the groups with the same or higher MIC and dosage (16.2% vs 35.8%; P = .041). Multivariate analysis identified septic shock (P < .001), C/T MIC >2 mg/L (P = .045), and increasing Charlson Comorbidity Index (P = .019) as independent predictors of mortality. Conclusions. The effectiveness of C/T in P. aeruginosa LRI was associated with an MIC <= 2 mg/L, and the lowest mortality was observed when HDo was administered for strains with C/T MIC <= 2 mg/L. HDo was not statistically associated with a better outcome. eng Ceftolozane/tazobactam Multidrug-resistant Pneumonia Pseudomonas aeruginosa Tracheobronchitis Higher MICs (> 2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam research article